Search

A metal-free cascade coupling/iodoaminocyclization reaction for the rapid assembly of 2-trifluoromethyl-imidazolines has been disclosed. The transformation applies readily accessible trifluoroacetimidoyl chlorides, allylamines and N-iodosuccinimides as the starting substrates, achieving an efficient and straightforward pathway to construct diverse imidazoline derivatives. Excellent efficiency of the reaction is observed (higher than 90% isolated yield for half of the examples), and the obtained imidazoline products bearing a pendent iodomethyl group could be easily transformed into other synthetically valuable compounds.

The activation of imidazoline 1 (I1) receptors is suggested to stimulate the respiratory drive in newborn rats. Here, we immunohistochemically examined whether nischarin, an I1 receptor candidate protein, is expressed in the ventrolateral medulla, where cardiorespiratory centers are located. Newborn rats (age, 3–5 days) were deeply anesthetized with isoflurane; the brainstem was dissected, sectioned sagittally, and labeled with nischarin. Nischarin-associated signals were observed broadly throughout the newborn rat brainstem, including at motor nuclei (motor trigeminal nucleus and facial nucleus), sensory nuclei (lateral superior olive, medial and spinal vestibular nuclei, cuneate nucleus, spinal trigeminal nucleus, and solitary nucleus), and the rostral and caudal ventrolateral medullar regions. In particular, the rostral ventrolateral medulla included a layer of aggregated nischarin expression along the ventral surface, and the layer was in close contact with GFAP-positive processes. In addition, some Phox2b-positive neurons were positive for nischarin in the region. Our results reveal nischarin expression in the newborn rat brainstem and suggest that I1 receptor activation at the level of the ventrolateral medulla contributes to central chemoreception and respiratory control in newborn rats.

Dexmedetomidine (DEX), an α2-adrenoreceptor (α2-AR) and imidazoline receptor agonist, is most often used for the sedation of patients in the intensive care unit. Its administration is associated with an increased incidence of bradycardia; however, the precise mechanism of DEX-induced bradycardia has yet to be fully elucidated. This study was undertaken to examine whether DEX modifies pacemaker activity and the underlying ionic channel function through α2-AR and imidazoline receptors. The whole-cell patch-clamp techniques were used to record action potentials and related ionic currents of sinoatrial node cells in guinea pigs. DEX (≥10 nM) reduced sinoatrial node automaticity and the diastolic depolarization rate. DEX reduced the amplitude of hyperpolarization-activated cation current (If or Ih) the pacemaker current, even within the physiological pacemaker potential range. DEX slowed the If current activation kinetics and caused a significant shift in the voltage dependence of channel activation to negative potentials. In addition, efaroxan, an α2-AR and imidazoline I1 receptor antagonist, attenuated the inhibitory effects of DEX on sinoatrial node automaticity and If current activity, whereas yohimbine, an α2-AR-selective antagonist, did not. DEX did not affect the current activities of other channels, including rapidly and slowly activating delayed rectifier K+ currents (IKr and IKs), L-type Ca2+ current (ICa,L), Na+/Ca2+ exchange current (INCX), and muscarinic K+ current (IK,ACh). Our results indicate that DEX, at clinically relevant concentrations, induced a negative chronotropic effect on the sinoatrial node function through the downregulation of If current through an imidazoline I1 receptor other than the α2-AR in the clinical setting.

A facile solid-phase synthetic method for incorporating the imidazoline ring motif, a surrogate for a trans peptide bond, into bioactive peptides is reported. The example described is the synthesis of an imidazoline peptidomimetic analog of an insect pyrokinin neuropeptide via a cyclization reaction of an iminium salt generated from the preceding amino acid and 2,4-diaminopropanoic acid (Dap).

BACKGROUND: Ventricular-like human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) exhibit the electrophysiological characteristics of spontaneous beating. Previous studies demonstrated that dexmedetomidine (DMED), a highly selective and widely used α(2)-adrenoceptor agonist for sedation, analgesia, and stress management, may induce antiarrhythmic effects, especially ventricular tachycardia. However, the underlying mechanisms of the DMED-mediated antiarrhythmic effects remain to be fully elucidated. METHODS: A conventional patch-clamp recording method was used to investigate the direct effects of DMED on spontaneous action potentials, pacemaker currents (I(f)), potassium (K(+)) channel currents (I(K1) and I(Kr)), sodium (Na(+)) channel currents (I(Na)), and calcium (Ca(2+)) channel currents (I(Ca)) in ventricular-like hiPSC-CMs. RESULTS: DMED dose-dependently altered the frequency of ventricular-like spontaneous action potentials with a half-maximal inhibitory concentration (IC(50)) of 27.9 µM (n=6) and significantly prolonged the action potential duration at 90% repolarization (APD(90)). DMED also inhibited the amplitudes of the I(Na) and I(Ca) without affecting the activation and inactivation curves of these channels. DMED decreased the time constant of the Na(+) and Ca(2+) channel activation at potential –40 to –20 mv, and –20 mv. DMED increased the time constant of inactivation of the Na(+) and Ca(2+) channels. However, DMED did not affect the I(K1), I(Kr), I(f), and their current-voltage relationship. The ability of DMED to decrease the spontaneous action potential frequency and the Na(+) and Ca(2+) channel amplitudes, were not blocked by yohimbine, idazoxan, or phentolamine. CONCLUSIONS: DMED could inhibit the frequency of spontaneous action potentials and decrease the I(Na) and I(Ca) of hiPSC-CMs via mechanisms that were independent of the α(2)-adrenoceptor, the imidazoline receptor, and the α(1)-adrenoceptor. These inhibitory effects on hiPSC-CMs may contribute to the antiarrhythmic effects of DMED.

C24H32N9O13Y, monoclinic, P21/n (no. 14), a = 12.237(3) Å, b = 11.058(3) Å, c = 23.235(6) Å, β = 98.486(4)°, V = 3109.6(14) Å3, Z = 4, R gt(F) = 0.0455, wR ref(F 2) = 0.0903, T = 293 K.

Imidazoline receptor of the first type (I1R) in addition to the established inhibition of sympathetic neurons may mediate the direct control of myocellular functions. Earlier, we revealed that I1-mediated signaling in the normotensive rat cardiomyocytes suppresses the nitric oxide production by endothelial NO synthase, impairs sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA) activity, and elevates intracellular calcium in the cytosol. Also, I1-agonists counteract β-adrenoceptor stimulation effects in respect to voltage-gated calcium currents. This study ascertains the I1R signal transduction in the normotensive Wistar and SHR cardiomyocytes. Reduction of Ca2+-currents by rilmenidine, a specific agonist of I1R, ensued from the phosphatidylcholine-specific phospholipase C-mediated activation of protein kinase C. There is a stimulation of serine/threonine phosphatase activity. In SHR cardiomyocytes, both the rilmenidine, and putative endogenous ligand, agmatine, almost twofold less effectively reduced L-type of Ca2+-currents. Average mRNA level of Nischarin, established functional component of I1R, is slightly decreased in SHR, as well as the intracellular Nischarin pool immunolabeled in the cytosol of SHR cardiomyocytes. Disturbance of I1R signal transduction in SHR may aggravate the development of this cardiovascular pathology.

Pharmacotherapies for fibromyalgia treatment are lacking. This study examined the antinociceptive and antidepressant-like effects of imidazoline I2 receptor (I2R) agonists in a reserpine-induced model of fibromyalgia in rats. Rats were treated for 3 days with vehicle or reserpine. The von Frey filament test was used to assess the antinociceptive effects of I2 receptor agonists, and the forced swim test was used to assess the antidepressant-like effects of these drugs. 2-BFI (3.2-10 mg/kg, intraperitoneally), phenyzoline (17.8-56 mg/kg, intraperitoneally), and CR4056 (3.2-10 mg/kg, intraperitoneally) all dose-dependently produced significant antinociceptive effects, which were attenuated by the I2R antagonist idazoxan. Only CR4056 significantly reduced the immobility time in the forced swim test in both vehicle-treated and reserpine-treated rats. These data suggest that I2R agonists may be useful to treat fibromyalgia-related pain and comorbid depression.

Morphine is a potent opioid analgesic used to alleviate moderate or severe pain, but the development of drug tolerance and dependence limits its use in pain management. Our previous studies showed that the candidate protein for I1 imidazoline receptor, imidazoline receptor antisera-selected (IRAS)/Nischarin, interacts with μ opioid receptor (MOR) and modulates its trafficking. However, there is no report of the effect of IRAS on morphine tolerance and physical dependence. In the present study, we found that IRAS knockout (KO) mice showed exacerbated analgesic tolerance and physical dependence compared to wild-type (WT) mice by chronic morphine treatment. Chronic morphine treatment down-regulated the expression of MOR in spinal cord of IRAS KO mice, while had no significant effect on MOR expression in WT mice. We observed the compensatory increase of cAMP accumulation in spinal cord after morphine tolerance, and this change was more significant in KO mice than WT mice. Furthermore, KO mice showed more elevation in the phosphorylation of AMPA receptor GluR1-S845 than WT mice, while the total expression of GluR1 remained unchanged after morphine dependence. Altogether, these data suggest that IRAS may play an important role in the development of morphine tolerance and physical dependence in vivo through modulating MOR expression, as well as AMPA GluR1-S845 phosphorylation, which might be one of the mechanisms underlying the development of opiate addiction.

A series of unsymmetrical NNN′ ruthenium(II) complexes supported by a tridentate bipyridyl imidazoline ligand with variable steric hindrance (2a–c; R1 = tBu, iPr, or Bn) and electronic effect (2d–h; R2 = H, CH3, OCH3, Br, or NO2) were prepared. The molecular structures of ligands 1f and 1g, and Ru complex 2a were further determined by X-ray single-crystal diffraction. The catalytic activity of these eight complexes for α-alkylation of nitriles with alcohols was evaluated, which could be controlled by the substituents on the imidazoline moiety. Ru complex 2h bearing a strong electron-withdrawing group (R2 = NO2) demonstrated the highest catalytic activity, with alkylated nitriles achieved in up to 97% yield.

Aim: to investigate the functional interaction of α2-adrenergic and imidazoline receptors recently identified on the sarcolemma of isolated cardiomyocytes for regulation of the intracellular calcium and the production of the signal molecule of nitric oxide (NO).Materials and methods:experiments were performed on isolated left ventricular cardiomyocytes of Wistar rats. Potential-dependent Ca2+-currents were measured from the whole-cell by the patch-clamp method in “perforated-patch” configuration. The intracellular calcium and the production of nitric oxide were estimated from the changes in fluorescence intensity of the Ca2+-specific and NO-sensitive dyes at fluorescent or confocal microscope.Results:It has been shown that α2‑adrenergic and imidazoline receptor agonists inhibit L-type Ca2+-currents by themselves, but their effects do not develop against each other’s background. The blockade of key effector molecules: protein kinase B (Akt kinase) for α2‑adrenergic receptors, and protein kinase C for imidazoline receptors causes the action of agonists to become additive. Both the selective α2‑agonist, guanabenz, and the specific agonist of the first type imidazoline receptors, rilmenidine, show an additional inhibition of Ca2+-currents against the basal background already reduced by the activation of one of the two receptor systems. Wherein rilmenidine increases the level of free Ca2+in the cytosol, and guanabenz, on the contrary, decreases it. The action of guanabenz does not develop against the background of rilmenidine, although it, in turn, effectively increases the intracellular level of calcium in guanabenz-pretreated cardiac cells. Activation of α2‑adrenergic receptors leads to significant stimulation of the endothelial isoform of NO-synthase, and as a result to an increase in the NO level. Activation of imidazoline receptors itself does not affect NO synthesis but it prevents the production of NO induced by α2‑agonists.Conclusion:obtained data make it possible to formulate a number of useful recommendations for clinical practice, and also to clarify the non-central peripheral effects arising from the activation of α2‑adrenergic or imidazoline systems under conditions of endogenous hyperactivation on of the two systems.

Recently identified imidazoline receptors of the first type (I1Rs) on the cardiomyocyte's sarcolemma open a new field in calcium signaling research. In particular, it is interesting to investigate their functional interaction with other well-known systems, such as β-adrenergic receptors. Here we investigated the effects of I1Rs activation on L-type voltage-gated Ca2+-currents under catecholaminergic stress induced by the application of β-agonist, isoproterenol. Pharmacological agonist of I1Rs (I1-agonist), rilmenidine, and the putative endogenous I1-ligand, agmatine, have been shown to effectively reduce Ca2+-currents potentiated by isoproterenol. Inhibitory analysis shows that the ability to suppress voltage-gated Ca2+-currents by rilmenidine and agmatine is fully preserved in the presence of the protein kinase A blocker (PKA), which indicates a PKA-independent mechanism of their action. The blockade of NO synthase isoforms with 7NI does not affect the intrinsic effects of agmatine and rilmenidine, which suggests NO-independent signaling pathways triggered by I1Rs. A nonspecific serine/threonine protein phosphatase (STPP) inhibitor, calyculin A, abrogates effects of rilmenidine or agmatine on the isoproterenol-induced Ca2+-currents. Direct measurements of phosphatase activity in the myocardial tissues showed that activation of the I1Rs leads to stimulation of STPP, which could be responsible for the I1-agonist influences. Obtained data clarify peripheral effects that occur during activation of the I1Rs under endogenous catecholaminergic stress, and can be used in clinical practice for more precise control of heart contractility in some cardiovascular pathologies.

Acute kidney injury (AKI) is a frequent and serious complication of sepsis; however, there are currently no effective therapies. Inflammation and oxidative stress are the major mechanisms implicated in lipopolysaccharide (LPS)-induced AKI. Dexmedetomidine (DEX) has been reported to have remarkable anti-inflammatory and antioxidant effects. Here, we examined the renoprotective effects of DEX and potential underlying mechanisms in rats with LPS-induced AKI. We analyzed renal function and structure; serum inflammatory cytokine; renal oxidant and antioxidant levels; and renal expression of glycogen synthase kinase-3β (GSK-3β)/nuclear factor erythroid 2-related factor 2 (Nrf2) pathway-related proteins in rats 4 hr after administration of LPS. Pretreatment with DEX improved renal function and significantly reduced the levels of inflammatory cytokines and oxidative stress markers. Treatment with DEX and the GSK-3β inhibitor SB216367 promoted phosphorylation of GSK-3β, induced Nrf2 nuclear translocation, and increased transcription of the Nrf2 target genes heme oxygenase-1 and NAD(P)H quinone oxidoreductase-1, primarily in renal tubules. Alpha-2-adrenergic receptor (α2-AR) antagonist atipamezole and imidazoline I 2 receptor (I 2 R) antagonist idazoxan reversed the effects of DEX. These results suggest that the renoprotective effects of DEX are mediated via α2-AR and I 2 R-dependent pathways that reduce inflammation and oxidative stress through GSK-3β/Nrf2 signaling.

A cobalt-catalyzed asymmetric hydroboration of styrenes using an imidazoline phenyl picoliamide (ImPPA) ligand was first reported to deliver the valuable chiral secondary organoboronates with good ...

Background Locomotor sensitization to repeated ethanol (EtOH) administration is proposed to play a role in early and recurring steps of addiction. The present study was designed to examine the effect of agmatine on EtOH-induced locomotor sensitization in mice. Methods Mice received daily single intraperitoneal injection of EtOH (2.5 g/kg, 20 v/v) for 7 consecutive days. Following a 3-day EtOH-free phase, the mice were challenged with EtOH on day 11 with a single injection of EtOH. Agmatine (10 to 40 μg/mouse), endogenous agmatine enhancers (l-arginine [80 μg/mouse], arcaine [50 μg/mouse], aminoguanidine [25 μg/mouse]), and imidazoline receptor agonist/antagonists were injected (intracerebroventricular [i.c.v.]) either daily before the injection of EtOH during the 7-day development phase or on days 8, 9, and 10 (EtOH-free phase). The horizontal locomotor activity was determined on days 1, 3, 5, 7, and 11. Results Agmatine (20 to 40 μg/mouse) administration for 7 days (development phase) significantly attenuated the locomotor sensitization response of EtOH challenge on day 11. Further, the agmatine administered only during EtOH-free period (days 8, 9, and 10) also inhibited the enhanced locomotor activity on the 11th day to EtOH challenge as compared to control mice indicating blockade of expression of sensitization. Daily treatment (i.c.v.) with endogenous agmatine enhancers like l-arginine (80 μg/mouse) or arcaine (50 μg/mouse) and aminoguanidine (25 μg/mouse) restrained the development as well as expression of sensitization to EtOH. Imidazoline I1 receptor agonist, moxonidine, and I2 agonist, 2-BFI, not only decreased the development and expression of locomotor sensitization but also potentiated the effect of agmatine when employed in combination. Importantly, I1 receptor antagonist, efaroxan, and I2 antagonist, idazoxan, blocked the effect of agmatine, revealing the involvement of imidazoline receptors in agmatine-mediated inhibition of EtOH sensitization. Conclusions Inhibition of EtOH sensitization by agmatine is mediated through imidazoline receptors and project agmatine and imidazoline agents in the pharmacotherapy of alcohol addiction.

Objectives The objective of this study was to investigate the effects of a new I1-imidazoline receptor-selective pyrroline compound on the hemodynamic, metabolic and microvascular alterations in a high-fat diet (HFD)-induced model of metabolic syndrome in rats. Methods In total, twenty adult male Wistar rats were fed a high-fat diet (HFD, n = 20) for 20 weeks. Thereafter, the rats received a new pyrroline compound selective for I1-imidazoline receptors (LNP599; 10 mg/kg/day) or vehicle (n = 10/group) orally by gavage for 4 weeks. Functional microcirculation was assessed using intravital video microscopy, and structural microcirculation was evaluated using histochemical analysis. Results LNP599 induced concomitant reductions in the SBP, HR and plasma catecholamine levels. The animals treated with this new antihypertensive compound also presented an improvement in body weight and the metabolic parameters related to metabolic syndrome, such as the glucose and lipid profiles. These effects were accompanied by a reversal of the functional and structural capillary rarefaction in the skeletal muscle. Conclusions The modulation of the sympathetic nervous system by a selective agonist for I1-imidazoline receptors improves the hemodynamic and metabolic parameters in an experimental model of metabolic syndrome. LNP599 can also contribute to the restoration of microcirculatory parameters.

Experimental studies and clinical trials revealed the complex interconnections between imidazoline system and various other mediators such as epinephrine, norepinephrine; thus, explain their involvement in the pathophysiological mechanisms of different motor, behavioral and cognitive disturbances. In this study, we tested the influence induced by idazoxan and efaroxan on the cognitive performances in rats. Groups of 6 adult male Wistar rats were treated intraperitoneally according to the following protocol: group I (Control): distilled water 0.3 ml/100g; group II (IDZ): 3 mg/kg idazoxan and group III (EFR): 1 mg/kg efaroxan. The effects of the imidazoline receptor antagonists on the rats cognitive functions were assessed using the radial-arm maze, in order to count the time spent into the arms, the number of baited arms visited, but previously explored (working memory errors); the time taken to consume all baits and the number of entering in non-baited arms (reference memory errors). The data were expressed as mean +/- standard deviation, and statistically analyzed using SPSS version 17.0 Software for Windows, followed by ANOVA one-way method. The administration of IDZ, as well as of EFR was accompanied by a substantial diminution in the number of working memory errors, and the period of time to consume all baits, statistically significant (p[0.01) compared to control group. The use of these two imidazoline receptors antagonists resulted in a considerable decrease in the reference memory errors number, statistically significant (p[0.01) compared to the group treated with distilled water. The influence of IDZ on the evaluated parameters was more accentuated than the effects induced by EFR in all sessions of testing, in this behavioral experimental model. Our findings indicate that treatment with both imidazoline receptor antagonists, idazoxan and efaroxan was associated by a facilitation of the short-term memory retention, an enhancement of discriminative spatial learning, and an improvement of long-term memory performance in radial arm maze in rats.

The reactions of 1,1′-bis(3-methyl-4-imidazolin-2-selone)methane (L1) and 1,2-bis(3-methyl-4-imidazolin-2-selone)ethane (L2) with mesityltellurenyl iodide (MesTeI) [Mes = 2,4,6-Me3C6H2] yielded the neutral [L1·2MesTeI]·2CH2Cl2 and the ionic [L2·MesTe]2(MesTeI2)2 compounds, respectively, which were characterized by X-ray diffraction analysis. DFT (mPW1PW//LANL08d/def2-SVP) and NBO calculations, supported by structural and FT-Raman measurements, show that the latter compound represents the first example of an authentic mesityltellurenyl cation, [MesTe]+, stabilized within a [MesTe(B)2]+ (B = Lewis base) charge transfer adduct featuring a 3c-4e Se→Te←Se three-body system.

The inhibition action of the imidazole derivative on the corrosion of mild steel in 0.5 M Sulphuric acid was investigated by weight loss, polarization, Impedance and SEM. The PZC of mild steel was studied by AC impedance method. The polarization experiment revealed that IDZ is of mixed–type but slightly anodic control. Weight loss results obtained revealed that the imidazoline derivatives performed excellently as corrosion inhibitor with efficiency above 70% at 20ppm at 303 K. The optimum period of inhibition for IDZ was determined by weight loss studies. Its adsorption on mild steel obeys Tempkin isotherm. Quantum chemical parameters and Mulliken charge densities on the optimized structure of imidazoline derivative were calculated using GAUSSIAN 09 with B3LYP / 6-31G (d,p) basis set

The synthesized imidazoline phosphate quaternary ammonium salt has low stability, which is spontaneously and rapidly hydrolyzed to the long-chain fatty acid amide (LFA). The hydrolysate (LFA) has been found to be an efficient inhibitor for Q235 steel against CO2 corrosion, which yields a maximum value above 90% at a concentration of 1000 mg L−1. The LFA inhibitor acts as an anodic type inhibitor and its inhibition mechanism is a “negative catalysis effect”. The heteroatoms in the acyl, amine and phosphate groups in the LFA molecule are the active centers to bond with Fe atoms to form a chemisorbed film on the steel surface.

A novel chemotype topologically similar to known influenza virus PA endonuclease inhibitors has been designed. It was aimed to reproduce the extended topology of the known metal-chelating ligands with a p-phenylidene-linked bis-imidazoline scaffold. It was envisioned that aromatic groups introduced to this scaffolds via metal-catalyzed N-arylation (Buchwald-Hartwig or Chan-Evans-Lam) would contribute to lipophilic binding to the target and one of the imidazoline nitrogen atoms would ensure non-chelating coordination to the prosthetic divalent metal ion. The compounds displayed appreciable anti-influenza activity in vitro and substantial concentration window from the general cytotoxicity range. Docking analysis of low-energy poses of the most active compound (as well as their comparison to the binding of an inactive compound) revealed that these compounds reproduced similar binding components to a known PA endonuclease inhibitor and displayed similar binding pose and desired monodentate metal coordination, as was initially envisioned. These findings warrant further investigation of the mechanism of action of the newly discovered series.

Adsorption of self-assembled monolayer (SAM) of different imidazolines derivatives was investigated on Fe2O3 (0 0 0 1) surface with DFT calculations to understand their corrosion inhibition mechanism. Quantum chemistry calculations enable us acquiring a better insight on the nature of imidazoline/surface interactions, i.e. partly covalent bonds, and self-organization of imidazoline ring on the surface than the previous force field-based studies. The SAM is composed of a network of H-bonded inhibitors. The influence of the alkyl chain length of imidazoline derivatives, which form a hydrophobic barrier above the surface, on the energetic and structural properties of the SAM was evaluated.

2-hydroxy-3-(methylcyclohexenyl-isopropyl)-5-methylbenzylaminoethylnonylimidazolines were synthesized by the interaction of 2-(methylcyclohexynylisopropyl-4-methylphenols and aminoethylnonylimidazoline. Aminocompounds are purified from cycloalkylphenol by transferring them to hydrochloride salt. Further, aqueous solution of the hydrochloric acid amine salt is treated with a concentrated solution of NH4OH and free aminecompounds are isolated. The resulting amine is separated from water by benzene extraction. After benzene distillation, the residue is undergone to distillation under vacuum. Its physico-chemical characteristics and purity of the products are determined. The obtained products are tested as the thermostabilizers to polypropylene.

Alpha-adrenergic agonists, such as the Imidazoline derivatives (ImDs) of oxymetazoline and xylometazoline, are highly effective hemostatic agents. ImDs have not been widely used in dentistry but their use in medicine, specifically in ophthalmology and otolaryngology, warrants consideration for pulpal hemostasis. This review presents dental healthcare professionals with an overview of ImDs in medicine. ImD solutions have the potential to be more effective and biocompatible than existing topical hemostatic compounds in pulpal management. Through a comprehensive analysis of the pharmacology of ImDs and the microphysiology of hemostasis regulation in oral tissues, a conceptual model of pulpal management by ImD solutions is presented.

We present the first cyclic five-membered triel(I) carbenoides E(AmIm) for E = Ga, In, Tl; AmIm = amido imidazoline-2-imine, which fill the current gap between four- and six-membered triel(I) carbenoides supported by HGiso and HNacNac. Ga(AmIm) can act as a strong σ-donor ligand in transition metal complexes, while the intermediacy of the Al(I) carbenoide Al(AmIm) is rationalised based on the isolation of an Al(III) insertion product.

Background and objectives: The connections between the imidazoline system and multiple other neurotransmitter systems in the brain (adrenergic, dopaminergic, serotoninergic, glutamatergic, opioid) indicate the complexity of the mechanisms underlying motor activity and behavior. The aim of the present research was to investigate the effects of the combination of ephedrine (EPD) and imidazoline antagonists idazoxan (IDZ) and efaroxan (EFR) on the endurance performance in the treadmill test in rats. Materials and Methods: We used Wistar rats distributed as follows: Group 1 (Control) receiving distilled water 0.3 mL/100 g body weight, Group 2 (EPD) receiving 20 mg/kg ephedrine, Group 3 (EPD + IDZ) receiving 20 mg/kg ephedrine + 3 mg/kg idazoxan, Group 4 (EPD + EFR) receiving 20 mg/kg ephedrine + 1 mg/kg efaroxan. An additional group (C) of animals receiving 0.3 mL/100 g body weight distilled water (but not subjected) to effort was used. Endurance capacity was evaluated using a treadmill running PanLAB assay. The evaluation of the substances’ influence on oxidative stress was performed by spectrophotometric determination of superoxide dismutase (SOD) and glutathione peroxidase (GPX) activity. Results: Treatment with EPD-IDZ and EPD-EFR were correlated with a longer distance traveled on the belt and with a decrease in the necessary electric shocks to motivate the animal to continue running in the forced locomotion test. Additionally, an increase in the activity of antioxidant enzymes was found. Conclusions: Idazoxan and efaroxan potentiated the physical effort-related effects of ephedrine with regard to endurance capacity and antioxidant activity in rats.

Background and Purpose: The development of effective therapeutic strategies against Alzheimer's disease (AD) remains a challenge. I2 Imidazoline receptors (I2-IR) ligands have a neuroprotective role in AD. Moreover, co-treatment of acetylcholinesterase inhibitors with neuroprotective agents has shown better effects on the prevention of dementia. Here, we assessed the potential therapeutic effect of the I2-IR ligand LSL60101, donepezil, and their combination in 5XFAD mice. Experimental Approach: 5XFAD female mice were treated with low doses of LSL60101 (1 mg kg-1 day-1), donepezil (1 mg kg -1 day-1), and donepezil plus LSL60101 (1+1 mg kg-1 day-1), during 4 weeks per os. Novel object recognition, Morris water maze, open field, elevated plus maze, and three-chamber tests were employed to evaluate the cognitive and behavioural status after treatment. The effects of the treatments on AD-like pathology were assessed with immunohistochemistry, Western blot and qPCR. Key results: Chronic low-dose treatment with LSL60101 and donepezil reversed cognitive deficits and impaired social behaviour. LSL60101 treatment did not affect anxiety-like behaviour in contrast to donepezil. In the 5XFAD brains, LSL60101 and donepezil/LSL60101 treatments decreased Aβ-pathology and Tau hyperphosphorylation, and these alterations were accompanied by reduced microglia marker Iba-1 levels and increased Trem2 gene expression. LSL60601 and donepezil decreased glial fibrillary acidic protein (GFAP) astrocytic marker reactivity. However, only LSL60601 treatment significantly increased the synaptic markers' levels post-density 95 (PSD95) and synaptophysin (SYN). Conclusion and implications: Our results suggest that chronic low dose treatment with selective I2-IR ligands can be an effective treatment for AD and provide insights into combination treatments of symptomatic and disease-modifying drugs.

Background and Purpose: Activation of type 2 imidazoline receptors has been shown to exhibit neuroprotective properties including anti‐apoptotic and anti‐inflammatory effects, suggesting a potential therapeutic value in Alzheimer's disease (AD). Here, we explored the effects of the imidazoline‐2 ligand BU224 in a model of amyloidosis. Experimental Approach: Six‐month‐old female transgenic 5XFAD and wild‐type (WT) mice were treated intraperitoneally with 5‐mg·kg−1 BU224 or vehicle twice a day for 10 days. Behavioural tests were performed for cognitive functions and neuropathological changes were investigated by immunohistochemistry, Western blot, elisa and qPCR. Effects of BU224 on amyloid precursor protein (APP) processing, spine density and calcium imaging were analysed in brain organotypic cultures and N2a cells. Key Results: BU224 treatment attenuated spatial and perirhinal cortex‐dependent recognition memory deficits in 5XFAD mice. Fear‐conditioning testing revealed that BU224 also improved both associative learning and hippocampal‐ and amygdala‐dependent memory in transgenic but not in WT mice. In the brain, BU224 reduced levels of the microglial marker Iba1 and pro‐inflammatory cytokines IL‐1β and TNF‐α and increased the expression of astrocytic marker GFAP in 5XFAD mice. These beneficial effects were not associated with changes in amyloid pathology, neuronal apoptosis, mitochondrial density, oxidative stress or autophagy markers. Interestingly, ex vivo and in vitro studies suggested that BU224 treatment increased the size of dendritic spines and induced a threefold reduction in amyloid‐β (Aβ)‐induced functional changes in NMDA receptors. Conclusion and Implications: Sub‐chronic treatment with BU224 restores memory and reduces inflammation in transgenic AD mice, at stages when animals display severe pathology.

The first enantio- and diastereoselective synthesis of Tepe's human proteasome modulator is described. Routes to this and other highly substituted chiral imidazolines generally produce racemic material. Key to the route disclosed here is a gram-scale anti-selective aza-Henry reaction of an α-alkyl α-nitro ester nucleophile, catalyzed by a Bis(Amidine) [BAM] chiral proton complex, delivering the key intermediate in high yield as a single stereoisomer. The adduct is reduced to the amino ester and converted to an imidazoline.

The molecular characteristics of a TOFA/DETA based imidazoline inhibitor were evaluated by analysing the inhibitor protonation profile, the CMC and micelle size and the rate of acid-catalysed hydrolysis of the inhibitor to improve understanding of the corrosion inhibition performance of the main imidazoline component and its hydrolysis products. The ability of the TOFA/DETA imidazoline based corrosion inhibitor and its products of hydrolysis in retarding both uniform and localized corrosion were assessed and compared on wet-ground X65 carbon steel at 80 °C in CO2 saturated 3 wt % NaCl brines. The findings indicate that the imidazoline based inhibitor forms micellar solutions, with a characteristic micelle size of 18 ± 9 nm at the CMC (10 ± 1 ppm) in CO2 saturated 3 wt % NaCl brines, and that under such conditions (pH~4.1), the inhibitor is fully protonated which increases inhibitor solubility/dispersibility and enhances molecular adsorption of the positively charged imidazoline on the metal surface thereby improving inhibition performance. Hydrolysis of the imidazoline and amido-amine is acid-catalysed and the consumption of imidazoline follows a pseudo-first-order reaction mechanism with an activation energy of 72.0 ± 2.9 kJ mol-1. The study concludes that the pre-aged inhibitor has different effects on uniform and localized corrosion behavior of X65 carbon steel.

Two imidazoline derivatives (OI and MOI) were synthesized as highly efficient inhibitors, and their inhibition performances and mechanisms in CO2-containing solution were studied using weight loss measurements, electrochemical tests, surface analysis and theoretical calculations. The results indicate that OI and MOI show excellent inhibition efficiency. Especially for MOI, its inhibition efficiency is as high as 95.58% at 20 ppm. Theoretical calculations confirm that both inhibitors successfully adsorb on metal surface via chemisorption. MOI shows a better inhibition performance than OI, because the sulfhydryl in MOI can be used as a powerful adsorption site, effectively improving the adsorption ability of MOI.

Protein kinase C is the superfamily of intracellular effector molecules which control crucial cellular functions. Here, we for the first time did the percentage estimation of all known PKC and PKC-related isozymes at the individual cadiomyocyte level. Broad spectrum of PKC transcripts is expressed in the left ventricular myocytes. In addition to the well-known ‘heart-specific’ PKCα, cardiomyocytes have the high expression levels of PKCN1, PKCδ, PKCD2, PKCe. In general, we detected all PKC isoforms excluding PKCη. In cardiomyocytes PKC activity tonically regulates voltage-gated Ca2+-currents, intracellular Ca2+ level and nitric oxide (NO) production. Imidazoline receptor of the first type (I1R)-mediated induction of the PKC activity positively modulates Ca2+ release through ryanodine receptor (RyR), increasing the Ca2+ leakage in the cytosol. In cardiomyocytes with the Ca2+-overloaded regions of > 9–10 μm size, the local PKC-induced Ca2+ signaling is transformed to global accompanied by spontaneous Ca2+ waves propagation across the entire cell perimeter. Such switching of Ca2+ signaling in cardiac cells can be important for the development of several cardiovascular pathologies and/or myocardial plasticity at the cardiomyocyte level.

Based on the finding that a central antihypertensive agent with high affinity for I1-type imidazoline receptors ? rilmenidine, shows cytotoxic effects on cultured cancer cell lines, it has been suggested that imidazoline receptors agonists might have a therapeutic potential in the cancer therapy. Nevertheless, potential rilmenidine side effects caused by activation of α-adrenoceptors, or other associated receptors and enzymes, might hinder its therapeutic benefits. Considering that human α-adrenoceptors belong to the rhodopsin-like class A of G-protein-coupled receptors (GPCRs) it is reasonable to assume that imidazolines might have the affinity for other receptors from the same class. Therefore, to investigate possible off-target effects of imidazoline ligands we have prepared a reverse docking protocol on class A GPCRs, using imidazoline ligands and their decoys. To verify our in silico results, three ligands with high scores and three ligands with low scores were tested for antagonistic activity on α2- adrenoceptors.

Pyridazine derivatives, such as arylpiperazinylalkyl pyridazinones, display antinociceptive effects to thermal and chemical stimuli. Here, we extended our previous knowledge on the pharmacological profile of 4-amino-6-methyl-2-(3-(4-(4-methylcyclohexa-1,3-dien-1-yl)piperazin-1-yl)propyl)-5-vinylpyridazin-3(2H)-one, here referred as ET1, paving the way for the comprehension of its complete mechanism of action. To this aim, we have evaluated the mouse behavioural responses in several animal models of pain, the effect of ET1 in the murine model of zymosan-induced paw oedema and air-pouch, assessing the cytokines and the cellular phenotype and finally, an in vitro radioligand binding study was performed on a panel of 30 different receptors. In the formalin test, ET1 reduced both neurogenic and inflammatory phase of nociception induced by the aldehyde. Similarly, ET1 strongly reduced paw licking response in the capsaicin test, the abdominal stretching in the writhing test and the carrageenan-induced thermal hyperalgesia. ET1 also evoked a long-lasting reduction of thermal hyperalgesia. Furthermore, ET1 produced a long-lasting anti-inflammatory effect in the zymosan-induced mouse paw oedema and air-pouch through the selective inhibition of inflammatory monocytes recruitment and the modulation of IL-1β, IL-6, TNF-α and MCP-1. Binding experiments confirmed an inhibitory effect on adrenergic α1A, α1B and α2A receptors subtypes and, for the first time, a moderate affinity was observed for the following receptors: histamine H1, imidazoline I2, sigma non-opioid intracellular receptor 1 and σ2. These results prompt ET1 as a potent analgesic and anti-inflammatory agent, and support the possibility that it may be suitable for clinical applications in a wide-range of inflammatory-based diseases.

To maintain the integrity of the internal surfaces of the pipelines in oil and gas industry, chemicals, including corrosion inhibitors and biocides, are commonly dosed to prevent corrosion. Imidazoline and its derivatives are widely used corrosion inhibitors for the protection of oil pipelines, which have been shown effective in reducing general corrosion. As an effective biocide, free nitrous acid (FNA) is suitable to inhibit microbially influenced corrosion, induced by for example sulfate-reducing bacteria. In this paper, we hypothesize that the continuous addition of imidazoline and intermittent dosing of FNA, when used in combination, would yield effective control of both general and pitting corrosions. As a typical imidazoline derivative, N-b-hydroxyethyl oleyl imidazoline (HEI-17) was applied in conjunction with intermittent dosing of FNA in the experimental system, with the results compared with two control systems, one receiving HEI-17 only, and one receiving no chemical dosing. The corrosion properties were monitored with open circuit potential, electrochemical impedance spectroscopy, linear polarization resistance, 3D optical profiling, and weight-loss measurement. Following a single dose of FNA, the general corrosion rates in the experimental reactor dropped up to 50% of that in the reactor receiving continuous HEI-17 dosing (0.27 ± 0.04 vs. 0.54 ± 0.08 mm/y), but gradually recovered to 93.4% of that in 2.5 months. After the FNA treatment, the pitting corrosion was decreased by 64.6% compared with continuous HEI-17 dosing reactor for a month from measuring the cumulative distribution of the pitting depth. HEI-17 treatment alone showed moderate pitting corrosion inhibition effect (approx. 27%), and the FNA treatment inhibited the formation of deep pits effectively. The combined application of HEI-17 and FNA has shown synergistic effects and high efficiency in mitigating MIC in the simulated water injection system. This treatment strategy has strong potential to be applied in the practical oilfield operations.

OBJECTIVE To examine the effects of imidazoline and nonimidazoline α-adrenergic agents on aggregation of feline platelets. SAMPLE Blood samples from 12 healthy adult cats. PROCEDURES In 7 experiments, the effects of 23 imidazoline and nonimidazoline α-adrenoceptor agonists or antagonists on aggregation and antiaggregation of feline platelets were determined via a turbidimetric method. Collagen and ADP were used to initiate aggregation. RESULTS Platelet aggregation was not induced by α-adrenoceptor agonists alone. Adrenaline and noradrenaline induced a dose-dependent potentiation of ADP- or collagen-induced aggregation. Oxymetazoline and xylometazoline also induced a small potentiation of ADP-stimulated aggregation, but other α-adrenoceptor agonists did not induce potentiation. The α2-adrenoceptor antagonists and certain imidazoline α-adrenergic agents including phentolamine, yohimbine, atipamezole, clonidine, medetomidine, and dexmedetomidine inhibited adrenaline-potentiated aggregation induced by ADP or collagen in a dose-dependent manner. The imidazoline compound antazoline inhibited adrenaline-potentiated aggregation in a dose-dependent manner. Conversely, α1-adrenoceptor antagonists and nonimidazoline α-adrenergic agents including xylazine and prazosin were ineffective or less effective for inhibiting adrenaline-potentiated aggregation. Moxonidine also was ineffective for inhibiting adrenaline-potentiated aggregation induced by collagen. Medetomidine and xylazine did not reverse the inhibitory effect of atipamezole and yohimbine on adrenaline-potentiated aggregation. CONCLUSIONS AND CLINICAL RELEVANCE Adrenaline-potentiated aggregation of feline platelets may be mediated by α2-adrenoceptors, whereas imidazoline agents may inhibit in vitro platelet aggregation via imidazoline receptors. Imidazoline α-adrenergic agents may have clinical use for conditions in which there is platelet reactivity to adrenaline. Xylazine, medetomidine, and dexmedetomidine may be used clinically in cats with minimal concerns for adverse effects on platelet function.

Steel bars embedded in reinforced concrete are vulnerable to corrosion in high chloride environments. Bidirectional electromigration rehabilitation (BIEM) is a novel method to enhance the durability of reinforced concrete by extracting chloride out of concrete and introducing an inhibitor to the surface of the steel bar under the action of an electric field. During the migration process, a higher ionization capacity of the inhibitor with a symmetrical molecular structure was introduced. A new imidazoline inhibitor was, therefore, employed in this study due to its great ionization capacity. The effect of imidazoline and triethylenetetramine inhibitor on chloride migration, corrosion potential, and strength of concrete were explored. The research results showed that the effect of chloride extraction and electrochemical chloride extraction made no significant difference on the surface of the concrete, where chloride extraction efficiency was more than 70%, and the chloride extraction efficiency was more than 90% around the location of the steel. while a dry-wet cycle test, the potential of concrete increased by about 200 mV by mixing imidazoline inhibitor. The imidazoline inhibitor was found to be effective at facilitating chloride migration and ameliorating corrosion, meanwhile, it had a negligible impact on the concrete&rsquo, s strength.

The demand of eco-friendly and effective corrosion inhibitor has been devoted recently to protect the corrosion in metal protective industrial. So, to fulfill that objective, novel silane functional group Imidazoline compound (DAMO Imidazoline), has been successfully synthesized from methyl oleate and N-(2-Aminoethyl)-3-aminopropyltrimethoxysilane (DAMO). It will be used in alkyd paint formulations for increasing corrosion inhibition. The success of this compound synthesis was done using Fourier Transform-Infrared (FT-IR). The result of DAMO Imidazoline synthesized showed several peaks with a wavelength of 2921.25 cm−1 and 2851.78 cm−1 for the asymmetric and symmetric stretch vibration of methylene, 1647.81 cm−1 for amide C=O strength bond, 1462.67 cm−1 for N-H bonds stretch of imidazoline ring, for asymmetric stretching of Si-O-Si vibration in 1111.46–1250.32 cm−1 and 583.35–720.84 cm−1 of Si-O-C bond. DAMO Imidazoline was evaluated by using Tafel method as corrosion inhibitor on low carbon steel in 5 % NaCl concentration, in various concentration 0.08 to 0.44 wt.%. The result showed that the inhibitor had an excellent inhibition effectiveness at concentration 0.28 wt.%.

Imidazoline is an organic compound that widely used as a corrosion inhibitor. Based on its structure, imidazoline is a heterocyclic compound having a pendant group and hydrocarbon chain which important for its activity as corrosion inhibitor. This research was conducted to modify the imidazoline structure to increase its activity in inhibiting corrosion towards carbon steel. In this research, ester-imidazoline from aminoethylethanolamine (AEEA) and oleic acid (OA) was successfully synthesized with an equivalent ratio of 1:2 (mole/mole) in xylene solvent with various reaction times using MAOS (Microwave Assisted Organic Synthesis) method. The optimum yield was obtained at 9 min reached 87.53 % yield. Ester-imidazoline was analyzed using thin layer chromatography (TLC) and elucidated using FTIR, UV-Vis, and 1H-NMR spectral data. Furthermore, the ability of ester-imidazoline to inhibit corrosion was measured towards carbon steel in 1% NaCl with various concentrations using Tafel polarization method to afford the inhibition efficiency (% IE). The highest % IE was yielded in 100 ppm with % IE value of 51.26 %. This study reported the first modification of imidazoline to yield ester-imidazoline using MAOS method along with its anticorrosion activity.